Vardenafil in Pulmonary Arterial Hypertension

• DOI: 10.1164/rccm.201101-0093oc
• Publication Date: 2011-03-14T00:08:41Z
• Authors: Zhi-Cheng Jing; Zai-Xin Yu; Jie-Yan Shen; Bing-Xiang Wu; Kai-Feng Xu; Xian-Yang Zhu; Lei Pan; Zhuo-Li Zhang; Xue-Qin Liu; Yu-Shun Zhang; Xin Jiang; Nazzareno Galiè
• Keywords: Vardenafil

Although the phosphodiesterase type 5 inhibitors sildenafil and tadalafil have demonstrated efficacy in patients with pulmonary arterial hypertension (PAH), monotherapy these agents has not been conclusively shown to reduce clinical worsening events.To evaluate safety of inhibitor vardenafil Chinese PAH.In a randomized, double-blind, placebo-controlled study, 66 PAH were randomized 2:1 (5 mg once daily for 4 wk then twice daily; n = 44) or placebo (n 22) 12 weeks. Patients completing this phase treated open-label daily) further weeks.At Week 12, mean placebo-corrected 6-minute walking distance was increased (69 m; P < 0.001), improvement maintained at least 24 Vardenafil also cardiac index (0.39 L·min(-1)·m(-2); 0.005) decreased pressure vascular resistance (-5.3 mm Hg, 0.047; -4.7 Wood U, 0.003; respectively) 12. Four group (20%) one (2.3%) had events (hazard ratio 0.105; 95% confidence interval, 0.012-0.938; 0.044). associated only mild transient adverse events.Vardenafil is effective well tolerated dose daily.